Reconciling conflicting evidence in the evaluation of the MitraClip system: Assessment of and response to the MITRA-FR and COAPT trials by key stakeholders

Manuela Montagnon; Yenfu Chen; Amy Grove; Jieun Park; Jean-François Obadia; Xavier Armoiry

doi:10.1111/jebm.12614

Journal of Evidence-Based Medicine ›› 2024, Vol. 17 ›› Issue (2) : 253 -255. DOI: 10.1111/jebm.12614

LETTER

Reconciling conflicting evidence in the evaluation of the MitraClip system: Assessment of and response to the MITRA-FR and COAPT trials by key stakeholders

Author information +

History +

PDF

Cite this article

Download citation ▾

Manuela Montagnon, Yenfu Chen, Amy Grove, Jieun Park, Jean-François Obadia, Xavier Armoiry. Reconciling conflicting evidence in the evaluation of the MitraClip system: Assessment of and response to the MITRA-FR and COAPT trials by key stakeholders. Journal of Evidence-Based Medicine, 2024, 17(2): 253-255 DOI:10.1111/jebm.12614

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379(24): 2297–2306.

[2]	Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379(24): 2307–2318.

[3]	Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate functional mitral regurgitation. JACC: Cardiovasc Imag. 2019; 12(2): 353–362.

[4]	Lindenfeld J, Abraham WT, Grayburn PA, et al. Association of effective regurgitation orifice area to left ventricular end-diastolic volume ratio with transcatheter mitral valve repair outcomes: a secondary analysis of the COAPT trial. JAMA Cardiol. 2021; 6(4): 427.

[5]	Messika-Zeitoun D, Iung B, Armoiry X, et al. Impact of mitral regurgitation severity and left ventricular remodeling on outcome after MitraClip implantation. JACC: Cardiovascular Imaging. 2021; 14(4): 742–752.

[6]	Luc JGY, Hong JC, Cheung AW, et al. The MITRA-FR trial vs the COAPT trial: more complementary than contradictory? Ann Thorac Surg. 2019; 108(4): 965–968.

[7]	Heart valve disease presenting in adults: investigation and management. National Institute for Health and Care Excellence (NICE); 2021.

[8]	Obadia JF, Armoiry X, Iung B, et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention. 2015; 10(11): 1354–1360.

[9]	Chhatriwalla AK, Vemulapalli S, Holmes DR, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes. JACC: Cardiovascular Interventions. 2019; 12(14): 1342–1352.

[10]	Flacco ME, Manzoli L, Boccia S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol. 2015; 68(7): 811–820.

[11]	Abott. Abbott Reports Third-Quarter 2019 Results.

[12]

Armoiry X, Obadia JF, Auguste P, Connock M. Conflicting findings between the Mitra-Fr and the Coapt trials: implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation. Ferket B, editor. PLoS ONE. 2020; 15(11):e0241361.

[13]	Hameed I, Oakley CT, Ahmed A, et al. Analysis of physician use of social media. JAMA Netw Open. 2021; 4(7):e2118213.

RIGHTS & PERMISSIONS

2024 The Authors. Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.